NPJ Breast Cancer最新文献_第6页

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer. atezolizumab联合cobimetinib或idasanutlin治疗转移性雌激素受体阳性乳腺癌的Ib/II期临床试验

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-21 DOI: 10.1038/s41523-025-00773-4

Jessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, Violeta Sanchez, Andres A Ocampo, Jacey L Marshall, Julia A Steele, Melinda E Sanders, Ingrid A Mayer, Justin M Balko, Laura C Kennedy

{"title":"A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.","authors":"Jessica Mezzanotte-Sharpe, Brandie C Taylor, Paula I Gonzalez-Ericsson, Violeta Sanchez, Andres A Ocampo, Jacey L Marshall, Julia A Steele, Melinda E Sanders, Ingrid A Mayer, Justin M Balko, Laura C Kennedy","doi":"10.1038/s41523-025-00773-4","DOIUrl":"10.1038/s41523-025-00773-4","url":null,"abstract":"Despite the availability of numerous treatment options for metastatic estrogen receptor positive breast cancer, additional strategies are needed, particularly when tumors become endocrine resistant. This phase Ib/II study examined the clinical activity and safety of the novel combination of atezolizumab with molecularly targeted therapy inhibiting 1) the Ras/Raf/MEK signaling pathway with cobimetinib in TP53-mutant tumors (arm COBI) or 2) the TP53 regulator MDM2 with idasanutlin in TP53-wild-type tumors (arm IDA). Twelve patients were enrolled before the study closed early due to slow accrual. 2/7 patients in arm IDA had durable responses to treatment. 1/5 patients in arm COBI had stable disease. Interestingly, conservation of tumor-specific HLA-ABC expression was observed in nearly all patients with clinical benefit. There were several grade 3-4 toxicities, particularly cytopenias in arm IDA. While this study was limited by small sample sizes, there were observations of clinical activity, including one exceptional responder, that warrant further investigation.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"61"},"PeriodicalIF":6.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research. MBCRC倡导者研究人员计划（MARP）：将倡导者和研究人员作为癌症研究的合作伙伴联系起来。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-06-21 DOI: 10.1038/s41523-025-00771-6

Hillary S Andrews, Igor L Bado, Amy Beumer, Isaac S Chan, Janice Cowden, Debbie Denardi, Gloria V Echeverria, Brooke L Gates, Marybeth Gilliam, Christine Hodgdon, Adrian V Lee, Joan Mancuso, Julia Maues, Steffi Oesterreich, Michael Papanicolaou, Katherine E Pendleton, Bob Riter, Kelly Shanahan, Anh M Tran-Huynh, Pavitra Viswanath, Stephanie Walker, Alana L Welm, Michelle M Williams, Garhett L Wyatt, Josh Newby

{"title":"The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research.","authors":"Hillary S Andrews, Igor L Bado, Amy Beumer, Isaac S Chan, Janice Cowden, Debbie Denardi, Gloria V Echeverria, Brooke L Gates, Marybeth Gilliam, Christine Hodgdon, Adrian V Lee, Joan Mancuso, Julia Maues, Steffi Oesterreich, Michael Papanicolaou, Katherine E Pendleton, Bob Riter, Kelly Shanahan, Anh M Tran-Huynh, Pavitra Viswanath, Stephanie Walker, Alana L Welm, Michelle M Williams, Garhett L Wyatt, Josh Newby","doi":"10.1038/s41523-025-00771-6","DOIUrl":"10.1038/s41523-025-00771-6","url":null,"abstract":"Involving patient advocates as partners in cancer research improves research and provides favorable experiences for both the researcher and the advocate. Previous work demonstrates challenges to establishing relationships between researchers and advocates, including uncertainty about why the relationships are necessary, how to establish them, what to say, and how they should be structured. To overcome these challenges, we established the Metastatic Breast Cancer Research Conference (MBCRC) Advocate Researcher Program (MARP) at the MBCRC in 2023. We outline the approach to the program to serve as a model for others interested in performing similar activities and report findings from surveys to establish evidence about the value of these relationships. The program connected 21 pairs of researchers and advocates, and participants responded to surveys about their experience, largely describing positive outcomes. Our hope is that a program like this could be used at any cancer conference in the future as we continue to encourage advocates and researchers to work together.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"60"},"PeriodicalIF":7.6,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial. PARSIFAL试验中帕博西尼对激素受体阳性晚期乳腺癌反应的生物标志物。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-20 DOI: 10.1038/s41523-025-00777-0

Joan Albanell, Angelo Gámez Pozo, Carlos L Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac

{"title":"Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.","authors":"Joan Albanell, Angelo Gámez Pozo, Carlos L Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Eileen Shimizu, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac","doi":"10.1038/s41523-025-00777-0","DOIUrl":"10.1038/s41523-025-00777-0","url":null,"abstract":"Currently, there are no clinically actionable biomarkers to predict patient to cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy for hormone receptor (HR)[+]/ human epidermal growth factor receptor 2 (HER2)[-] advanced breast cancer (ABC). Herein, we report an exploratory biomarker substudy (transFAL) from a subset of patients included in PARSIFAL, a phase II randomized clinical trial that evaluated first-line palbociclib plus fulvestrant or letrozole for HR[+]/HER2[-] ABC. No definitive biomarkers were discovered, however, worse outcomes were found with CDK6 postivity (p = 0.008), ER negativity (p = 0.008), high Ki67 (p = 0.04), and TP53 mutation (p = 0.04). ctDNA density (p = 0.036) and number of mutations (p = 0.033) at baseline were significantly higher for resistant patients. Our study reveals future directions to explore in the goal to determine biomarkers of response to CDK4/6i.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"59"},"PeriodicalIF":6.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2- breast cancer. 使用70基因检测的个性化新辅助策略增加ER+/HER2-乳腺癌的保乳手术

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-20 DOI: 10.1038/s41523-025-00772-5

Wonshik Han, Eunhye Kang, Ji Gwang Jung, Hong-Kyu Kim, Han-Byoel Lee, Jisun Kim, Sae Byul Lee, Hee-Chul Shin, Chan Sub Park, Min-Ki Seong, Hyun-Ah Kim, Eun-Kyu Kim, Byung Ho Son

{"title":"Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2- breast cancer.","authors":"Wonshik Han, Eunhye Kang, Ji Gwang Jung, Hong-Kyu Kim, Han-Byoel Lee, Jisun Kim, Sae Byul Lee, Hee-Chul Shin, Chan Sub Park, Min-Ki Seong, Hyun-Ah Kim, Eun-Kyu Kim, Byung Ho Son","doi":"10.1038/s41523-025-00772-5","DOIUrl":"10.1038/s41523-025-00772-5","url":null,"abstract":"We investigated whether tailored neoadjuvant therapy (chemotherapy [NCT] or endocrine therapy [NET]) guided by a 70-gene assay could improve breast-conserving surgery (BCS) rates among patients with ER-positive/HER2-negative breast cancer initially deemed ineligible for BCS. Of 130 prospectively enrolled patients (stage II-IIIA, across four Korean centers), 92 were analyzed. Patients classified as high genomic risk received NCT, while low-risk patients underwent NET (letrozole ± leuprolide for premenopausal women) for 16-24 weeks. The primary endpoint-achieving the surgeon-defined target tumor size for BCS-was reached in 69.6% (95% CI: 59.1-78.7%), significantly surpassing the predefined goal of 50.8% (p < 0.05). The actual overall BCS rate was 59.8% (64.7% NCT, 45.8% NET). Pathologic complete response occurred in 2.2%, exclusively in the NCT group. Thus, pretreatment genomic profiling effectively guided therapy selection, substantially increasing BCS eligibility while sparing low-risk patients unnecessary chemotherapy toxicity.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"57"},"PeriodicalIF":6.5,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. 循环肿瘤DNA的个性化突变跟踪预测高危早期乳腺癌患者的复发。

IF 7.6 2区医学

NPJ Breast Cancer Pub Date : 2025-06-20 DOI: 10.1038/s41523-025-00778-z

Sao Trung Nguyen, Van-Anh Nguyen Hoang, Vu Nguyen Trieu, Thanh Huyen Pham, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Nguyen, Dao Nguyen Vinh, Thanh Thuy Thi Do, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Hoa Giang, Lan N Tu

{"title":"Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer.","authors":"Sao Trung Nguyen, Van-Anh Nguyen Hoang, Vu Nguyen Trieu, Thanh Huyen Pham, Thi Cuc Dinh, Dinh Hoang Pham, Ngoc Nguyen, Dao Nguyen Vinh, Thanh Thuy Thi Do, Duy Sinh Nguyen, Hoai-Nghia Nguyen, Hoa Giang, Lan N Tu","doi":"10.1038/s41523-025-00778-z","DOIUrl":"10.1038/s41523-025-00778-z","url":null,"abstract":"The clinical utilization of circulating tumor DNA (ctDNA) in breast cancer (BC) management is not well-defined. In this prospective study, 168 patients with early-stage BC were recruited, serial blood samples were collected before and after surgery. Tumor-informed ctDNA testing was performed, which sequenced tumors for 95 genes followed by bespoke mPCR to track 1-9 mutations in the plasma. ctDNA was detected before surgery in 14.6%, 40.0%, 83.8%, and 80.0% of HR+ low-risk, HR+ high-risk, HR-HER2+ and HR-HER2- patients, respectively. Pre-operative ctDNA positivity was significantly associated with decreased disease-free survival (DFS) (adjusted HR = 3.09, 95% CI 2.65-80.0, p = 0.001). After a median 26.6-month follow-up, 11 patients relapsed, and ctDNA at landmark time point 2-4 weeks after surgery was detected in 50.0% (5/10) of cases. Landmark ctDNA clearance was associated with significantly longer DFS (p = 0.0009) and positive ctDNA persistence after adjuvant therapy occurred in 36.4% (4/11) of stage-III patients. During surveillance, ctDNA detection had 90.9% sensitivity and 98.8% specificity to predict recurrence, and median lead time of 9.7 months. Patients with detected ctDNA had shorter DFS than those with undetectable ctDNA (adjusted HR = 207.05, 95% CI 41.38- > 1000, p = 0.001). Therefore, ctDNA status both before and after surgery could help stratify recurrence risk for BC patients.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"58"},"PeriodicalIF":7.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stroma content in triple-negative breast cancer spheroid models regulates penetration and efficacy of tumor-targeting Salmonella typhimurium. 三阴性乳腺癌球形模型中基质含量调节肿瘤靶向鼠伤寒沙门菌的渗透和疗效。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-19 DOI: 10.1038/s41523-025-00770-7

Y Zhan, B Saha, B Burkel, E J Leaman, S M Ponik, B Behkam

{"title":"Stroma content in triple-negative breast cancer spheroid models regulates penetration and efficacy of tumor-targeting Salmonella typhimurium.","authors":"Y Zhan, B Saha, B Burkel, E J Leaman, S M Ponik, B Behkam","doi":"10.1038/s41523-025-00770-7","DOIUrl":"10.1038/s41523-025-00770-7","url":null,"abstract":"Bacteria-based cancer therapy (BBCT) has not yet conferred clinical survival advantages in solid tumors, partly due to limited colonization. Collagen is well-known to hinder the penetration and efficacy of many therapeutic modalities in solid tumors. Nevertheless, the effect of collagen on BBCT efficacy remains largely unexplored. We hypothesized that collagen limits the distribution and, thereby, the efficacy of tumor-selective Salmonella Typhimurium VNP20009. By comparing high and low collagen-content triple-negative breast cancer spheroid models, we found that high collagen content reduces bacterial distribution by ~4.5-fold and antitumor effect by 61%. Mathematical modeling of bacteria intratumoral distribution shows that a 10-fold lower diffusivity in collagen-rich tumors is responsible for the observed outcomes. Single-cell resolution imaging corroborates these findings, revealing bacteria accumulation behind collagen-rich regions, wherein collagen acts as a physical barrier for motile bacteria. Discovering the interplay between collagen content and BBCT performance opens new opportunities for engineering BBCT strains with improved efficacy.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"56"},"PeriodicalIF":6.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in contralateral breast cancer and contralateral prophylactic mastectomy from 2009 to 2016. 2009 - 2016年对侧乳腺癌及对侧预防性乳房切除术趋势。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-14 DOI: 10.1038/s41523-025-00763-6

Shana J Kim, Jasleen Arneja, Rebecca A G Christensen, Geoff M Anderson, Jennifer D Brooks

引用次数: 0

Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer. 基线细胞周期和免疫谱表明CDK4/6抑制剂在转移性HR + /HER2-乳腺癌中的应答。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-12 DOI: 10.1038/s41523-025-00767-2

Stephanie L Tzetzo, Emily Schultz, Jianxin Wang, Hanna R Rosenheck, Sidney Mahan, Erik S Knudsen, Agnieszka K Witkiewicz

{"title":"Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer.","authors":"Stephanie L Tzetzo, Emily Schultz, Jianxin Wang, Hanna R Rosenheck, Sidney Mahan, Erik S Knudsen, Agnieszka K Witkiewicz","doi":"10.1038/s41523-025-00767-2","DOIUrl":"10.1038/s41523-025-00767-2","url":null,"abstract":"While CDK4/6 inhibitors (CDK4/6i) and endocrine therapy are standard-of-care for metastatic HR + /HER2- breast cancer, patient selection for durable efficacy remains undefined. Here, we assessed baseline cell cycle and immune profiles in a CDK4/6i-treated patient cohort with differential progression-free survival (PFS < 6 months vs. >23 months) using transcriptomic and protein-based imaging approaches. Cell cycle, polo-like kinase signaling and transcription gene sets are largely enriched among pre-treatment tissue of patients with short PFS. Pre-treatment tumors express cyclin A or E significantly higher in patients with short PFS and correlate with macrophage accumulation. Patients with long PFS display gene set enrichment for growth factor and immune signaling pre-treatment, while gene set enrichment for immune activation emerges during CDK4/6i therapy. Our data highlight baseline tumor-intrinsic and tumor microenvironments-associated indicators of CDK4/6i response in the \"real-world\" setting and offer implications for precision-based therapeutic combinations to enhance CDK4/6i efficacy. Clinical trial registration number: NCT04526587.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"54"},"PeriodicalIF":6.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention. 筛选乳腺癌预防有效药物和优化剂量的机会之窗试验。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-09 DOI: 10.1038/s41523-025-00745-8

G Aurilio, D Serrano, M Lazzeroni, A Guerrieri-Gonzaga, H Johansson, S Gandini, I M Briata, M D'Amico, S Spinaci, P Veronesi, V Galimberti, M Intra, B M Heckman-Stoddard, E Szabo, G Viale, B Bonanni, A DeCensi

引用次数: 0

Inflammatory breast cancer, best practice in the community setting. 炎性乳腺癌，在社区环境下的最佳实践。

IF 6.5 2区医学

NPJ Breast Cancer Pub Date : 2025-06-07 DOI: 10.1038/s41523-025-00765-4

Yoko Takahashi, Nithya Sridhar, Toshiaki Iwase, Ashley Marumoto, Jami Fukui, Aiesha Pradhan, Yee Chung Cheng, Naoto T Ueno

{"title":"Inflammatory breast cancer, best practice in the community setting.","authors":"Yoko Takahashi, Nithya Sridhar, Toshiaki Iwase, Ashley Marumoto, Jami Fukui, Aiesha Pradhan, Yee Chung Cheng, Naoto T Ueno","doi":"10.1038/s41523-025-00765-4","DOIUrl":"10.1038/s41523-025-00765-4","url":null,"abstract":"Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer typically diagnosed at advanced stages. Although many cases initially respond to conventional therapies, IBC remains refractory, with high risk of recurrence due to early dissemination, tumor heterogeneity, and complex microenvironmental factors. Despite advancements in treatment, IBC poses unique challenges, particularly in community healthcare settings, where implementation of current guidelines is often limited by disease complexity and evidence gaps. Multidisciplinary care is essential and should include education on therapeutic options, lymphedema management, financial navigations, and ongoing support. To support diagnostic consistency, a consensus-driven IBC Scoring System has been developed to help clinicians identify IBC more accurately using clinical features This paper reviews best practices for managing IBC in community settings, emphasizing practical, multidisciplinary strategies that improve outcomes and presenting a framework aligns with the realities of community healthcare to ensure patients receive the highest possible standard of care.","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"52"},"PeriodicalIF":6.5,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0